Abali, H.Yavuz, S.Calikusu, Z.Seyrek, E.2023-02-212023-02-212015-01-0110.1093/annonc/mdu473https://hdl.handle.net/11443/1130http://dx.doi.org/10.1093/annonc/mdu473This letter criticize the design of ACTS-CC trialpatients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.ArticleWOS:000347416300037